Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesis

1 Jul 1995

Abstract excerpt

The beta-thalassaemias represent a heterogenous group of diseases resulting from decreased erythroid beta-globin mRNA expression and imbalanced alpha/beta-globin chain synthesis which are manifest clinically by ineffective erythropoiesis and excessive haemolysis. Increasing levels of haemoglobin F (HbF) by pharmacological agents has been proposed to ameliorate the severity of the disease by improving the balance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 7646994
DOI: 10.1111/j.1365-2141.1995.tb05584.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesisPMID 7646994Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Semantic proximity Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

Successful Use of Hydroxyurea in β-Thalassemia MajorSemantic proximity Read ↗

Understanding α‐globin gene regulation and implications for the treatment of β‐thalassemiaSemantic proximity Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.Semantic proximity Read ↗

Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.Semantic proximity Read ↗

Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.Semantic proximity Read ↗

Response to hydroxyurea therapy in beta-thalassemia.Semantic proximity Read ↗

Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.